I agree that my overly optimistic projection of a $36 buyout in the past was likely wrong without a big surprise like dramatic sales growth, a COVID-trial breakthrough or astounding outcomes in the Alzheimer's trial.
But I think a reasonable buyout would be worth between $26 and $36 a share. Anything lower and a debt-free company sitting on a half billion dollars cash with many partnership opportunities around the globe might just sit back and let the cash roll in. It's not in a panic-sell situation like many small pharmas that lack capital.
Most of us think a buyout is the company's best option because we want a quick payoff, particularly if we're underwater right now. But Amarin might not think that way at all.
News 
Market Data 
Discover 
